journal
MENU ▼
Read by QxMD icon Read
search

Blood Cancer Journal

journal
https://www.readbyqxmd.com/read/28212374/the-effect-of-body-mass-index-at-diagnosis-on-clinical-outcome-in-children-with-newly-diagnosed-acute-lymphoblastic-leukemia
#1
H M Eissa, Y Zhou, J C Panetta, E K Browne, S Jeha, C Cheng, M V Relling, D Campana, C-H Pui, H Inaba
The impact of body mass index (BMI) at diagnosis on treatment outcome in children with acute lymphoblastic leukemia (ALL) is controversial. We studied 373 children with ALL enrolled on the Total XV study, which prospectively used minimal residual disease (MRD) for risk assignment. MRD on day 19 and at the end of remission induction (day 46), cumulative incidence of relapse/refractory disease (CIR), event-free survival (EFS) and overall survival (OS) were evaluated using sets of four, three and two subgroups based on BMI at diagnosis, along with BMI percentile change during remission induction...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28212373/poly-adp-ribose-polymerase-1-mrna-levels-strongly-correlate-with-the-prognosis-of-myelodysplastic-syndromes
#2
P Diamantopoulos, K Zervakis, P Zervakis, M Sofotasiou, T Vassilakopoulos, I Kotsianidis, A Symeonidis, V Pappa, A Galanopoulos, E Solomou, E Kodandreopoulou, V Papadopoulou, P Korkolopoulou, M Mantzourani, G Kyriakakis, N-A Viniou
Poly (ADP-ribose) polymerase 1 (PARP-1) has a central role in the repair of DNA breaks and is a promising treatment target in malignancy. We measured PARP1 mRNA levels by a SYBR-green-based PCR in the bone marrow of 74 patients with myelodysplastic syndrome (MDS) and correlated them to their demographic, hematologic and prognostic characteristics. The median PARP1 mRNA levels were correlated to the type of MDS (2008/2016 WHO classification, P=0.005) and to the IPSS score (P=0.002). A correlation was also found with the IPSS-R score (P=0...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28211889/clinical-utility-of-the-revised-international-staging-system-in-unselected-patients-with-newly-diagnosed-and-relapsed-multiple-myeloma
#3
N Tandon, S V Rajkumar, B LaPlant, A Pettinger, M Q Lacy, A Dispenzieri, F K Buadi, M A Gertz, S R Hayman, N Leung, R S Go, D Dingli, P Kapoor, Y Lin, Y L Hwa, A L Fonder, M A Hobbs, S R Zeldenrust, J A Lust, W I Gonsalves, S J Russell, S K Kumar
We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28211888/discrepancies-between-the-percentage-of-plasma-cells-in-bone-marrow-aspiration-and-bm-biopsy-impact-on-the-revised-imwg-diagnostic-criteria-of-multiple-myeloma
#4
N Lee, S Y Moon, J-H Lee, H-K Park, S-Y Kong, S-M Bang, J H Lee, S-S Yoon, D S Lee
No abstract text is available yet for this article.
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28211887/germline-mutations-predisposing-to-diffuse-large-b-cell-lymphoma
#5
REVIEW
O C Leeksma, N F de Miranda, H Veelken
Genetic studies of diffuse large B-cell lymphomas (DLBCLs) in humans have revealed numerous targets of somatic mutations and an increasing number of potentially relevant germline alterations. The latter often affect genes involved in DNA repair and/or immune function. In general, defects in these genes also predispose to other conditions. Knowledge of these mutations can lead to disease-preventing measures in the patient and relatives thereof. Conceivably, these germline mutations will be taken into account in future therapy of the lymphoma...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28211886/a-novel-approach-for-the-identification-of-efficient-combination-therapies-in-primary-human-acute-myeloid-leukemia-specimens
#6
I Baccelli, J Krosl, G Boucher, I Boivin, V-P Lavallée, J Hébert, S Lemieux, A Marinier, G Sauvageau
Appropriate culture methods for the interrogation of primary leukemic samples were hitherto lacking and current assays for compound screening are not adapted for large-scale investigation of synergistic combinations. In this study, we report a novel approach that efficiently distills synthetic lethal interactions between small molecules active on primary human acute myeloid leukemia (AML) specimens. In single-dose experiments and under culture conditions preserving leukemia stem cell activity, our strategy considerably reduces the number of tests needed for the identification of promising compound combinations...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28211885/the-novel-bmi-1-inhibitor-ptc596-downregulates-mcl-1-and-induces-p53-independent-mitochondrial-apoptosis-in-acute-myeloid-leukemia-progenitor-cells
#7
Y Nishida, A Maeda, M J Kim, L Cao, Y Kubota, J Ishizawa, A AlRawi, Y Kato, A Iwama, M Fujisawa, K Matsue, M Weetall, M Dumble, M Andreeff, T W Davis, A Branstrom, S Kimura, K Kojima
Disease recurrence is the major problem in the treatment of acute myeloid leukemia (AML). Relapse is driven by leukemia stem cells, a chemoresistant subpopulation capable of re-establishing disease. Patients with p53 mutant AML are at an extremely high risk of relapse. B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) is required for the self-renewal and maintenance of AML stem cells. Here we studied the effects of a novel small molecule inhibitor of BMI-1, PTC596, in AML cells. Treatment with PTC596 reduced MCL-1 expression and triggered several molecular events consistent with induction of mitochondrial apoptosis: loss of mitochondrial membrane potential, BAX conformational change, caspase-3 cleavage and phosphatidylserine externalization...
February 17, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157219/the-role-of-the-extracellular-matrix-in-primary-myelofibrosis
#8
REVIEW
O Leiva, S K Ng, S Chitalia, A Balduini, S Matsuura, K Ravid
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm that arises from clonal proliferation of hematopoietic stem cells and leads to progressive bone marrow (BM) fibrosis. While cellular mutations involved in the development of PMF have been heavily investigated, noteworthy is the important role the extracellular matrix (ECM) plays in the progression of BM fibrosis. This review surveys ECM proteins contributors of PMF, and highlights how better understanding of the control of the ECM within the BM niche may lead to combined therapeutic options in PMF...
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157218/expanded-safety-analysis-of-pevonedistat-a-first-in-class-nedd8-activating-enzyme-inhibitor-in-patients-with-acute-myeloid-leukemia-and-myelodysplastic-syndromes
#9
R T Swords, J Watts, H P Erba, J K Altman, M Maris, F Anwer, Z Hua, H Stein, H Faessel, F Sedarati, B J Dezube, F J Giles, B C Medeiros, D J DeAngelo
No abstract text is available yet for this article.
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157217/acute-myeloid-leukemia-targets-for-bispecific-antibodies
#10
REVIEW
S S Hoseini, N K Cheung
Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behind. Bispecific antibodies can redirect polyclonal effector cells to engage chosen targets on leukemia blasts. When the effector cells are natural-killer cells, both antibody-dependent and antibody-independent mechanisms could be exploited...
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157216/ibrutinib-in-previously-treated-chronic-lymphocytic-leukemia-patients-with-autoimmune-cytopenias-in-the-resonate-study
#11
M Montillo, S O'Brien, A Tedeschi, J C Byrd, C Dearden, D Gill, J R Brown, J C Barrientos, S P Mulligan, R R Furman, F Cymbalista, C Plascencia, S Chang, E Hsu, D F James, P Hillmen
No abstract text is available yet for this article.
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157215/identification-of-a-genetically-defined-ultra-high-risk-group-in-relapsed-pediatric-t-lymphoblastic-leukemia
#12
P Richter-Pechańska, J B Kunz, J Hof, M Zimmermann, T Rausch, O R Bandapalli, E Orlova, G Scapinello, J C Sagi, M Stanulla, M Schrappe, G Cario, R Kirschner-Schwabe, C Eckert, V Benes, J O Korbel, M U Muckenthaler, A E Kulozik
In the search for genes that define critical steps of relapse in pediatric T-cell acute lymphoblastic leukemia (T-ALL) and can serve as prognostic markers, we performed targeted sequencing of 313 leukemia-related genes in 214 patients: 67 samples collected at the time of relapse and 147 at initial diagnosis. As relapse-specific genetic events, we identified activating mutations in NT5C2 (P=0.0001, Fisher's exact test), inactivation of TP53 (P=0.0007, Fisher's exact test) and duplication of chr17:q11.2-24.3 (P=0...
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157214/differential-depth-of-treatment-response-required-for-optimal-outcome-in-patients-with-blast-phase-versus-chronic-phase-of-chronic-myeloid-leukemia
#13
Z Chen, L J Medeiros, H M Kantajian, L Zheng, Z Gong, K P Patel, H Xiong, W Wang, J E Cortes, S Hu
No abstract text is available yet for this article.
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157213/validation-of-a-vitamin-d-replacement-strategy-in-vitamin-d-insufficient-patients-with-lymphoma-or-chronic-lymphocytic-leukemia
#14
J G Sfeir, M T Drake, B R LaPlant, M J Maurer, B K Link, T J Berndt, T D Shanafelt, J R Cerhan, T M Habermann, A L Feldman, T Witzig
No abstract text is available yet for this article.
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28128792/ifn-%C3%AE-induces-greater-antiproliferative-and-proapoptotic-effects-and-increased-p53-signaling-compared-with-ifn-%C3%AE-in-pbmcs-of-adult-t-cell-leukemia-lymphoma-patients
#15
T Dierckx, R Khouri, S M Menezes, D Decanine, L Farre, A Bittencourt, A M Vandamme, J Van Weyenbergh
No abstract text is available yet for this article.
January 27, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28106878/late-effects-in-survivors-of-infantile-acute-leukemia-a-study-of-the-l-e-a-program
#16
V Gandemer, J Bonneau, C Oudin, J Berbis, Y Bertrand, M-D Tabone, S Ducassou, P Chastagner, B Brethon, J-H Dalle, S Thouvenin, M Poiree, D Plantaz, J Kanold, N Sirvent, P Lutz, Z Hamidou, A Baruchel, G Leverger, P Auquier, G Michel
No abstract text is available yet for this article.
January 20, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28106877/investigating-heredity-in-cutaneous-t-cell-lymphoma-in-a-unique-cohort-of-danish-twins
#17
N Odum, L M Lindahl, M Wod, T Krejsgaard, A Skytthe, A Woetmann, L Iversen, K Christensen
No abstract text is available yet for this article.
January 20, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157190/familial-associations-of-lymphoma-and-myeloma-with-autoimmune-diseases
#18
K Hemminki, A Försti, K Sundquist, J Sundquist, X Li
Many B-cell neoplasms are associated with autoimmune diseases (AIDs) but most evidence is based on a personal rather than a family history of AIDs. Here we calculated risks for non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL) and multiple myeloma (MM) when family members were diagnosed with any of 44 different AIDs, or, independently, risk for AIDs when family members were diagnosed with a neoplasm. A total of 64 418 neoplasms and 531 155 AIDs were identified from Swedish nationwide health care records...
January 6, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157189/identification-of-cell-type-specific-mutations-in-nodal-t-cell-lymphomas
#19
T B Nguyen, M Sakata-Yanagimoto, Y Asabe, D Matsubara, J Kano, K Yoshida, Y Shiraishi, K Chiba, H Tanaka, S Miyano, K Izutsu, N Nakamura, K Takeuchi, H Miyoshi, K Ohshima, T Minowa, S Ogawa, M Noguchi, S Chiba
Recent genetic analysis has identified frequent mutations in ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 2 (IDH2) and ras homolog family member A (RHOA) in nodal T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. We examined the distribution of mutations in these subtypes of mature T-/natural killer cell neoplasms to determine their clonal architecture. Targeted sequencing was performed for 71 genes in tumor-derived DNA of 87 cases...
January 6, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28157188/stat5a-5b-specific-expansion-and-transformation-of-hematopoietic-stem-cells
#20
S Ghanem, K Friedbichler, C Boudot, J Bourgeais, V Gouilleux-Gruart, A Régnier, O Herault, R Moriggl, F Gouilleux
No abstract text is available yet for this article.
January 6, 2017: Blood Cancer Journal
journal
journal
43747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"